Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.

Associations between dyslipidemia and metabolic dysfunction-associated steatotic liver disease (MASLD) have been reported. Previous studies have shown that the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio may be a surrogate marker of MASLD, assessed by liver ultrasound. However, no studies have evaluated the utility of this ratio according to biopsy-proven MASLD and its stages. Therefore, our aim was to evaluate if the TG/HDL-C ratio allows for the identification of biopsy-proven MASLD in patients with obesity. We conducted a case-control study in 153 patients with obesity who underwent metabolic surgery and had a concomitant liver biopsy. Fifty-three patients were classified as no MASLD, 45 patients as metabolic dysfunction-associated steatotic liver-MASL, and 55 patients as metabolic dysfunction-associated steatohepatitis-MASH. A receiver operating characteristic (ROC) analysis was performed to assess the accuracy of the TG/HDL-C ratio to detect MASLD. We also compared the area under the curve (AUC) of the TG/HDL-C ratio, serum TG, and HDL-C. A higher TG/HDL-C ratio was observed among patients with MASLD, compared with patients without MASLD. No differences in the TG/HDL-C ratio were found between participants with MASL and MASH. The greatest AUC was observed for the TG/HDL-C ratio (AUC 0.747, p < 0.001) with a cut-off point of 3.7 for detecting MASLD (sensitivity = 70%; specificity = 74.5%). However, no statistically significant differences between the AUC of the TG/HDL-C ratio and TG or HDL-C were observed to detect MASLD. In conclusion, although an elevated TG/HDL-C ratio can be found in patients with MASLD, this marker did not improve the detection of MASLD in our study population, compared with either serum TG or HDL-C.

The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes.

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely tied to obesity. The degree ranges from steatosis (MASL) and steatohepatitis (MASH) to liver cirrhosis. PCSK9 controls cholesterol and lipid particle transport to the liver. PCSK9 might interfere with the pathophysiology of MASLD and bariatric surgery (BS) outcomes of patients with MASLD. OBJECTIVES: Evaluate the relationship between serum and hepatic PCSK9 levels with the degree of MASLD and the metabolic outcome of BS. SETTING: University Hospital, Spain. METHODS: A total of 110 patients with obesity undergoing BS were classified according to liver histology as controls, MAS, and MASH. PCSK9 levels in serum were measured before and 6 months after BS using enzyme-linked immunosorbent assay. PCSK9 protein and mRNA levels in liver tissue were analyzed by immunohistochemistry and reverse transcriptase-polymerase chain reaction, respectively. RESULTS: Hepatic PCSK9 protein levels were diminished in MASL and MASH compared with patients without MASLD and showed a strong negative association with MASLD severity scores. Liver PCSK9 mRNA was higher in MASH compared with controls and MASL and showed positive associations with MASLD severity scores. There were no differences in serum PCSK9 pre or postBS between the groups. Pre- and postsurgery serum PCSK9 positively correlated with cholesterol fold-changes and body mass index (BMI), cholesterol, and low-density lipoprotein -cholesterol fold-changes, respectively. PCSK9 fold-change positively correlated with BMI changes and was the sole variable explaining BMI fold changes in a regression model. CONCLUSIONS: PCSK9 mRNA and protein in the liver might be associated with the degree of MASLD. Serum PCSK9 may be associated with cholesterol and/or BMI fold changes. Serum changes of PCSK9 after BS could explain BMI loss outcome.

Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity.

CONTEXT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development. OBJECTIVE: To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors. METHODS: This was a case-control study in patients with obesity undergoing bariatric surgery at a University Hospital between January 2020 and December 2021. Participants were distributed in three groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction-associated steatohepatitis (n = 32). Hepatic and serum FAs levels were determined by GC-MS. The nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by RT-qPCR. RESULTS: The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared to those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD being significantly different between the three groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD. CONCLUSION: Alterations in hepatic FA levels in MASLD patients were due to an enhancement of the de novo lipogenesis in the liver.

Hepatic and serum branched-chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case-control study.

OBJECTIVE: Alterations in the hepatic lipidome are a crucial factor involved in the pathophysiology of nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate the serum and hepatic profile of branched-chain fatty acids (BCFAs) in patients with different stages of NAFLD. METHODS: This was a case-control study performed in 27 patients without NAFLD, 49 patients with nonalcoholic fatty liver, and 17 patients with nonalcoholic steatohepatitis, defined by liver biopsies. Serum and hepatic levels of BCFAs were analyzed by gas chromatography-mass spectrometry. The hepatic expression of genes involved in the endogenous synthesis of BCFAs was analyzed by real-time quantitative polymerase chain reaction (RT-qPCR). RESULTS: A significant increase in hepatic BCFAs was found in subjects with NAFLD compared with those without NAFLD; no differences were observed in serum BCFAs between study groups. Trimethyl BCFAs, iso-BCFAs, and anteiso-BCFAs were increased in subjects with NAFLD (either nonalcoholic fatty liver or nonalcoholic steatohepatitis) compared with those without NAFLD. Correlation analysis showed a relationship between hepatic BCFAs and the histopathological diagnosis of NAFLD, as well as other histological and biochemical parameters related to this disease. Gene expression analysis in liver showed that the mRNA levels of BCAT1, BCAT2, and BCKDHA were upregulated in patients with NAFLD. CONCLUSIONS: These results suggest that the increased production of liver BCFAs might be related to NAFLD development and progression.

New challenges in cholangiocarcinoma candidates for elective surgery: harnessing the microbiome dysbiosis.

BACKGROUND: The gut microbiota, composed by several species of microorganisms, works to preserve the liver-gut homeostasis and plays an important role during digestion and absorption of nutrients, and in the immune response of the host. In this review, we analyzed the influence of microbiota in patients with cholangiocarcinoma (CCA) who were candidates for elective surgery. METHODS: A literature review was conducted to identify papers that provided empiric evidence to support that the altered microbiota composition (dysbiosis) is related also to CCA development. RESULTS: Bacteria such as Helicobacter pylori, Helicobacter hepaticus, and Opisthorchis viverrini increase the risk of CCA. The most abundant genera were Enterococcus, Streptococcus, Bacteroides, Klebsiella, and Pyramidobacter in CCA's biliary microbiota. Additionally, levels of Bacteroides, Geobacillus, Meiothermus, and Anoxybacillus genera were significantly higher. An enrichment of Bifidobacteriaceae, Enterobacteriaceae, and Enterococcaceae families has also been observed in CCA tumor tissue. Microbiota is related to postoperative outcomes in abdominal surgery. The combination of caloric restriction diets in liver cancer or CCA increases the effect of the chemotherapy treatment. CONCLUSION: The correct use of nutrition for microbiota modulation according to each patient's needs could be a therapeutic tool in combination with elective surgery and chemotherapy to diminish side effects and improve prognosis. Further investigations are needed to fully understand the mechanisms by which they are related.

Optimizing the Preparation of Silk Fibroin Nanoparticles and Their Loading with Polyphenols: Towards a More Efficient Anti-Inflammatory Effect on Macrophages.

Silk fibroin nanoparticles (SFN) have become a promising tool in drug delivery systems due to their physicochemical characteristics. SFN have shown their outstanding properties as an active vehicle for polyphenols, enhancing their antioxidant and anti-inflammatory effects on macrophages; therefore, it becomes necessary to have an easy, reproducible and scalable production method. In order to improve the production of nanoparticles, we performed direct precipitation of non-dialyzed silk fibroin solutions and evaluated the reproducibility of the method using dynamic light scattering. We also studied the loading efficiency of three different natural polyphenols using propylene glycol as a solvent. The loaded nanoparticles were fully characterized and used to treat human macrophage cells to assess the anti-inflammatory activity of these nanoparticles. The measured hydrodynamic characteristics of the SFN and the overall yield of the process showed that the new preparation method is highly reproducible and repeatable. Thus, we not only present a new scalable method to prepare silk nanoparticles but also how to improve the loading of natural polyphenolic compounds to the SFN, as well as the important anti-inflammatory effects of these loaded nanoparticles in a cell model of human macrophage cells.

Anti-Leukemic Activity of Brassica-Derived Bioactive Compounds in HL-60 Myeloid Leukemia Cells.

Acute myeloid leukemia (AML) is a cancer of the myeloid blood cells mainly treated with chemotherapy for cancer remission, but this non-selective treatment also induces numerous side effects. Investigations with bioactive compounds from plant-derived foods against cancer have increased in the last years because there is an urgent need to search for new anti-leukemic agents possessing higher efficacy and selectivity for AML cells and fewer negative side effects. In this study, we analyzed the anti-leukemic activity of several phytochemicals that are representative of the major classes of compounds present in cruciferous foods (glucosinolates, isothiocyanates, hydroxycinnamic acids, flavonols, and anthocyanins) in the human acute myeloid leukemia cell line HL-60. Our results revealed that among the different Brassica-derived compounds assayed, sulforaphane (SFN) (an aliphatic isothiocyanate) showed the most potent anti-leukemic activity with an IC50 value of 6 µM in dose-response MTT assays after 48 h of treatment. On the other hand, chlorogenic acid (a hydroxycinnamic acid) and cyanidin-3-glucoside (an anthocyanin) also displayed anti-leukemic potential, with IC50 values of 7 µM and 17 µM after 48 h of incubation, respectively. Importantly, these compounds did not show significant cell toxicity in macrophages-like differentiated cells at 10 and 25 µM, indicating that their cytotoxic effects were specific to AML cancer cells. Finally, we found that these three compounds were able to induce the NRF2/KEAP1 signaling pathway in a dose-dependent manner, highlighting SFN as the most potent NRF2 activator. Overall, the present evidence shed light on the potential for using foods and ingredients rich in anticancer bioactive phytochemicals from Brassica spp.

Dr.C. Juan Amado Díaz Sarduy: fundador de la Escuela de Medicina de la Universidad de Oriente / DSc. Juan Amado Díaz Sarduy: founder of the Medicine School of Oriente University

Con este artículo se pretende rescatar parte de la fructífera y larga vida del Dr. Juan Amado Díaz Sarduy, profesor titular y de mérito, además de doctor honoris causa de la Universidad de Ciencias Médicas de Santiago de Cuba. El texto es un tributo a tan insigne médico, al revolucionario íntegro y verdadero mentor de la Imagenología en esta provincia. Su reciente fallecimiento, el 28 de marzo de 2022, deja un profundo sentimiento de tristeza en quienes le conocieron; pero quedan su ejemplo, siempre en la primera fila de todas las batallas, y los recuerdos imperecederos de su nobleza espiritual, de la fidelidad a sus amigos y el amor a su familia.

With this work it is hoped to rescue part of Dr. Juan Amado Díaz Sarduy fruitful and long life, associate and merit professor, besides his honorary doctorate degree of the University of Medical Sciences in Santiago de Cuba. The text is a tribute to such famous doctor, upright revolutionary and true mentor of Imaging in this province. His recent death, on March 28, 2022, leaves a deep feeling of sadness in those that knew him; but his example remains, always in the first line of all battles, and the everlasting memories of his spiritual nobility, fidelity to his friends and love to his family.

Dietary modulation of gut microbiota in patients with colorectal cancer undergoing surgery: A review.

Colorectal cancer (CRC) is the third most frequent malignancy and the second cause of cancer death worldwide. Several factors have been postulated to be involved in CRC pathophysiology, including physical inactivity, unhealthy dietary habits, obesity, and the gut microbiota. Emerging data suggest that the microbiome may play a key role in CRC prognosis and derived complications in patients undergoing colorectal surgery. On the other hand, dietary intervention has been demonstrated to be able to induce significant changes in the gut microbiota and related metabolites in different conditions; therefore, the manipulation of gut microbiota through dietary intervention may constitute a useful approach to improve perioperative dysbiosis and post-surgical outcomes in patients with CRC. In this article, we review the role of the gut microbiota in CRC surgery complications and the potential therapeutic modulation of gut microbiome through nutritional intervention in patients with CRC undergoing surgery.

Gut Microbiome Modification through Dietary Intervention in Patients with Colorectal Cancer: Protocol for a Prospective, Interventional, Controlled, Randomized Clinical Trial in Patients with Scheduled Surgical Intervention for CRC.

Colorectal cancer (CRC) is the third most common cancer and the second cause of cancer death worldwide. Several factors have been postulated to be involved in CRC pathophysiology, including heritable and environmental factors, which are the latest to be closely associated with nutritional habits, physical activity, obesity, and the gut microbiota. The latter may also play a key role in CRC prognosis and derived complications in patients undergoing surgery. This is a single-center, open, controlled, randomized clinical trial, in patients with scheduled surgical intervention for CRC. The primary objective is to assess whether a pre-surgical nutritional intervention, based on a high-fiber diet rich in polyunsaturated fatty acids (PUFAs), can reduce disturbances of the gut microbiota composition and, consequently, the rate of post-surgical complications in patients with CRC. Patients will be randomized in a 1:1 ratio after receiving a diagnosis of CRC. In the control arm, patients will receive standard nutritional recommendations, while patients in the intervention arm will be advised to follow a high-fiber diet rich in PUFAs before surgery. Participants will be followed up for one year to evaluate the overall rate of postsurgical complications, recurrences of CRC, response to adjuvant therapy, and overall/disease-free survival.

Leptin Signaling in Obesity and Colorectal Cancer.

Obesity and colorectal cancer (CRC) are among the leading diseases causing deaths in the world, showing a complex multifactorial pathology. Obesity is considered a risk factor in CRC development through inflammation, metabolic, and signaling processes. Leptin is one of the most important adipokines related to obesity and an important proinflammatory marker, mainly expressed in adipose tissue, with many genetic variation profiles, many related influencing factors, and various functions that have been ascribed but not yet fully understood and elucidated, the most important ones being related to energy metabolism, as well as endocrine and immune systems. Aberrant signaling and genetic variations of leptin are correlated with obesity and CRC, with the genetic causality showing both inherited and acquired events, in addition to lifestyle and environmental risk factors; these might also be related to specific pathogenic pathways at different time points. Moreover, mutation gain is a crucial factor enabling the genetic process of CRC. Currently, the inconsistent and insufficient data related to leptin's relationship with obesity and CRC indicate the necessity of further related studies. This review summarizes the current knowledge on leptin genetics and its potential relationship with the main pathogenic pathways of obesity and CRC, in an attempt to understand the molecular mechanisms of these associations, in the context of inconsistent and contradictory data. The understanding of these mechanisms linking obesity and CRC could help to develop novel therapeutic targets and prevention strategies, resulting in a better prognosis and management of these diseases.

Analysis of the anti-inflammatory potential of Brassica bioactive compounds in a human macrophage-like cell model derived from HL-60 cells.

BACKGROUND: Chronic inflammatory diseases are major causes of global morbidity and mortality. Acute inflammation is meant to protect the body against foreign agents, but it also plays a major role in tissue repairment. Several mediators are involved in this process, including pro-inflammatory cytokines produced by macrophages. Occasionally, if the inflammatory response is not resolved, the acute inflammatory process can evolve into a chronic inflammation. Natural compounds from vegetables are considered as an important source of active agents with potential to treat or prevent inflammatory related pathologies and could be used as an alternative of the therapeutic agents currently in use, such as non-steroidal anti-inflammatory drugs (NSAIDs), which present several side effects. METHODS: In this research work we evaluated in vitro the anti-inflammatory activity of a series of ten phytochemicals present in Brassica, measured as the potential of those compounds to reduce the production of key pro-inflammatory cytokines (TNF-α, IL-6 and IL-1ß) by a human macrophage-like cell model of HL-60 cells RESULTS: Most of the tested phytochemicals (including the most representative bioactive molecules of the major classes of compounds present in cruciferous foods such as glucosinolates, isothiocyanates, hydroxycinnamic acids, flavonols and anthocyanins) demonstrated significant anti-inflammatory activity at micromolar level in the absence of cytotoxic effects in this human macrophage-like cell model. CONCLUSION: These data confirm that phytochemicals commonly obtained from Brassica may be potential therapeutic leads to treat or prevent human chronic inflammation and related diseases.

Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery.

Nonalcoholic fatty liver disease (NAFLD) is increasing in parallel with the rising prevalence of obesity, leading to major health and socioeconomic consequences. To date, the most effective therapeutic approach for NAFLD is weight loss. Accordingly, bariatric surgery (BS), which produces marked reductions in body weight, is associated with significant histopathological improvements in advanced stages of NAFLD, such as nonalcoholic steatohepatitis (NASH) and liver fibrosis. BS is also associated with substantial taxonomical and functional alterations in gut microbiota, which are believed to play a significant role in metabolic improvement after BS. Interestingly, gut microbiota and related metabolites may be implicated in the pathogenesis of NAFLD through diverse mechanisms, including specific microbiome signatures, short chain fatty acid production or the modulation of one-carbon metabolism. Moreover, emerging evidence highlights the potential association between gut microbiota changes after BS and NASH resolution. In this review, we summarize the current knowledge on the relationship between NAFLD severity and gut microbiota, as well as the role of the gut microbiome and related metabolites in NAFLD improvement after BS.

Lic. María Elena Jiménez Arias (1948˗2021): artífice de la revista Medisan / Lic. María Elena Jiménez Arias (1948-2021): author of Medisan magazine

Con este artículo se desea honrar la memoria de la Lic. María Elena Jiménez Arias, fundadora del Centro Provincial de Información de Ciencias Médicas de Santiago de Cuba y artífice de la revista Medisan, quien, desde un profundo conocimiento de la lengua española y el amor por su profesión, se dedicó a revisar y mejorar estilísticamente documentos biomédicos de muy variada índole durante cuatro décadas. Asimismo, fue loable su interés y placer en enseñar a redactar y publicar sobre medicina y otras ciencias afines, lo cual le concedió un meritorio lugar en la comunidad de profesionales de la salud de esta provincia y en el grupo de editores científicos de toda Cuba.

With this work it is wanted to honor the memory of the Lic. María Elena Jiménez Arias, founder of the Information Provincial Center of Medical Sciences from Santiago de Cuba and author of Medisan magazine, who, from a deep knowledge of the Spanish language and the love for her profession, devoted her life to stylistically revise and improve biomedical documents of very varied nature during four decades. Also, her interest and pleasure in teaching how to edit and publish on medicine and other similar sciences was commendable, that granted her a meritorious place in the community of health professionals from this province and in the group of scientific editors of all Cuba.

Dr. Antonio María Béguez César (1895-1975): fundador y maestro de la Sociedad Cubana de Pediatría de Santiago de Cuba / Dr. Antonio María Béguez César (1895-1975): founder and teacher of the Pediatrics Cuban Society in Santiago de Cuba

Con este artículo se buscó ampliar los datos biográficos del eminente científico cubano Antonio María Béguez César y divulgar aspectos poco conocidos de su prolífica existencia. Para ello se consultaron los archivos personales de la familia Béguez López y el índice de autores y materias del Boletín de la Sociedad Cubana de Pediatría y de la Revista Cubana de Pediatría, donde se consigna su bibliografía activa; además, se analizaron documentos de la época y se consideraron los testimonios de familiares, colegas y amigos del ilustre pediatra santiaguero. El trabajo forma parte del proyecto investigativo "Estrategia para incrementar la visibilidad del hallazgo científico del pediatra Dr. Antonio María Béguez César", que revela al descubridor de la "neutropenia crónica maligna familiar con granulaciones atípicas de los leucocitos", entidad clínica inscrita entre los diez hitos de la inmunología cubana, que ha sido erróneamente divulgada en el mundo científico-médico como síndrome de Chédiak-Higashi.

This work aimed at widen the biographical data of the eminent Cuban scientist Antonio María Béguez César and to spread not very well-known aspects of his prolific existence. The personal files of Béguez López family and the index of authors and matters of the Pediatrics Cuban Society Bulletin and the Pediatrics Cuban Magazine were consulted, where his active bibliography is consigned; also, documents of that time were analyzed and testimonies of family, colleagues and friends of the distinguished pediatrician from Santiago were considered. The work is part of the investigative project "Strategy to increase the visibility of the pediatrician Dr. Antonio María Béguez César scientific finding" that reveals the discoverer of "the family malignant chronic neutropenia with atypical granulations of the leukocytic cells", clinical entity inscribed among the ten landmarks of the Cuban immunology that has been erroneously spread in the scientific-medical world as Chediak-Higashi syndrome.

Síndrome de Béguez-Steinbrinck-Higashi: un nuevo epónimo para el síndrome de Chediak-Higashi / Béguez-Steinbrinck-Higashi syndrome: a new eponymous for the Chediak-Higashi syndrome

En diciembre de 1943, el Dr. Antonio María Béguez César detalló en el Boletín de la Sociedad Cubana de Pediatría los aspectos clínicos y hematológicos de una rara afección que padecieron tres niños de una familia santiaguera, quienes fallecieron en sus primeros años de vida. No había informes sobre hallazgos similares en la bibliografía médica, por lo cual se consideró la primera descripción de una enfermedad denominada por él como neutropenia crónica maligna familiar con granulaciones atípicas de los leucocitos, que aún hoy suele divulgarse erróneamente como síndrome de Chediak-Higashi y no como síndrome de Béguez-Steinbrinck-Higashi. Esta enfermedad es una inmunodeficiencia primaria causada por mutaciones en el gen regulador de la función lisosomal, capaz de alterar la formación del fagolisosoma en el neutrófilo y determinar la presencia de gránulos secretores gigantes en su interior, asociadas a un predominio de infecciones recurrentes generadas por bacterias piógenas. Aquí se realiza un recuento histórico del descubrimiento de esta entidad y se actualiza su fisiopatología(AU)

On December 1943, Dr. Antonio María Béguez César detailed in the Journal of the Cuban Pediatric Society the clinical and hematologic aspects of a rare disorder suffered by three children from a family in the locality, who expired during the first years of their lives in Santiago de Cuba. At that moment there was no report about similar findings in the medical literature, therefore it is considered the first description of a disease denominated by him as familial malignant chronic neutropenia with atypical granulations of leucocytes, misleadingly revealed as Chediak-Higashi syndrome instead of Béguez-Steinbrinck-Higashi syndrome. This disease consists of a primary immunodeficiency induced by mutations in the regulator gen of the lysosomal function, which is able to alter the formation of phagolysosoma in the neutrophil and determine the presence of giant secretor granules associated with the predominance of recurrent infections provoked by pyogen bacteria. Here, a brief history of it's discovery as well as an updating of it's physiopathology are carried out(AU)

El Dr Esteban Roberto Regalado García y su fidelidad imperecedera a la Declaración de Principios de Las Ardillas / Dr Esteban Roberto Regalado García and his immortal fidelity to the Principles Declaration of Las Ardillas

En este artículo se mencionan algunos aspectos de la acrisolada historia de vida del médico cubano Esteban Roberto Regalado García, quien el 27 de noviembre de 1960 fue designado por los estudiantes egresados del tercer curso de Medicina, después del 1ro de enero de 1959, para entregarle al Comandante en Jefe Fidel Castro Ruz, en un acto realizado en la escalinata de la Universidad de La Habana, una copia de la comunicación conocida como Declaración de principios; documento con fuerza de presente y presagio de futuro(AU)

In this work some aspects of the purified life history of the Cuban doctor Esteban Roberto Regalado García are mentioned, who on November 27th, 1960 was designated by the students graduated from the third course of Medicine, after January 1st, 1959, to present the Commander in Chief Fidel Castro Ruz, in a ceremony that took place in the Havana University steps; with a copy of the communication known as Declaration of principles; a document with present force and future presage

El Dr Esteban Roberto Regalado García y su fidelidad imperecedera a la Declaración de Principios de Las Ardillas / Dr Esteban Roberto Regalado García and his immortal fidelity to the Principles Declaration of Las Ardillas

En este artículo se mencionan algunos aspectos de la acrisolada historia de vida del médico cubano Esteban Roberto Regalado García, quien el 27 de noviembre de 1960 fue designado por los estudiantes egresados del tercer curso de Medicina, después del 1ro de enero de 1959, para entregarle al Comandante en Jefe Fidel Castro Ruz, en un acto realizado en la escalinata de la Universidad de La Habana, una copia de la comunicación conocida como Declaración de principios; documento con fuerza de presente y presagio de futuro.

In this work some aspects of the purified life history of the Cuban doctor Esteban Roberto Regalado García are mentioned, who on November 27th, 1960 was designated by the students graduated from the third course of Medicine, after January 1st, 1959, to present the Commander in Chief Fidel Castro Ruz, in a ceremony that took place in the Havana University steps; with a copy of the communication known as Declaration of principles; a document with present force and future presage.

A la memoria del Dr Antonio María Béguez César (1895-1975): descubridor de la neutropenia crónica maligna familiar con granulaciones atípicas de los leucocitos / In memory of Dr Antonio María Béguez César (1895-1975): discoverer of the family malignant chronic neutropenia with atypical granulations of the leukocytic cells

El Dr Antonio María Béguez César (1895-1975), médico cubano, considerado el Padre de la Pediatría en las provincias orientales de su país, descubrió en 1933 una rara enfermedad cuya descripción se divulgó 10 años después en el Boletín de la Sociedad Cubana de Pediatría, como neutropenia crónica maligna familiar con granulaciones atípicas de los leucocitos, aunque eso no impidió que otra persona se apropiara de la autoría del hallazgo científico, que ha sido conocido en el ámbito médico como síndrome de Chediak-Higashi. Si bien en la I Jornada Latinoamericana de Estudios Cooperativos en Hematología, celebrada en La Habana en febrero de 1973, se reconoció su descubrimiento, el silencio público al respecto se mantuvo hasta finales del pasado siglo y primeros años del XXI, cuando ya para siempre su vida y obra fundamentan a plenitud los homenajes perdurables que están dedicándose a su memoria, en consonancia con la verdad histórica y el rigor científico, y como muestra de desagravio al galeno que fue despojado de un mérito incuestionablemente suyo(AU)

Dr Antonio María Béguez César (1895-1975) was a Cuban physician, considered as Father of the Pediatrics in the eastern provincies of his country. He discovered a strange disease in 1933 whose description was spread 10 years later in the Bulletin of the Cuban Society of Pediatrics, as family malignant chronic neutropenia with atypical granulations of the leukocytic cells, although it didn't prevent that another person borrowed the scientific finding that has been known in the medical environment as Chédiak-Higashi syndrome. Although in the first Latin American Day of Hematology Cooperative Studies, taking place in Havana in February, 1973, his finding was recognized, the public silence in this respect remained until the end of last century and first years of the XXI, when already and ever his life and work fully support the long lasting homages that are being devoted to his memory, according to the historical truth and the scientific rigor, and as an example of apology to the physician whose unquestionably own merit was borrowed(AU)